Publications by authors named "Allison Cool"
Trends Pharmacol Sci
August 2024
Article Synopsis
- BTK inhibitors, especially the first-in-class ibrutinib, have significantly improved treatment for B cell lymphomas like chronic lymphocytic leukemia (CLL), but new options are emerging for better safety and efficacy.
- A noncovalent BTK inhibitor, pirtobrutinib, has recently been approved for tough-to-treat CLL cases, raising questions about its potential to replace covalent inhibitors in standard treatments.
- Ongoing advancements in BTK inhibitors and their degraders may reshape treatment strategies for B cell cancers and autoimmune diseases in the future, highlighting the evolving landscape of this field.
